Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study.
Liquid biopsy
Perfusion
Precision oncotherapy
Rectal cancer
Recurrence
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
13
09
2019
accepted:
09
10
2019
pubmed:
18
10
2019
medline:
30
1
2020
entrez:
18
10
2019
Statut:
ppublish
Résumé
Third line innovative systemic treatments and loco-regional chemotherapy by hypoxic pelvic perfusion (HPP) have both been proposed for the treatment of unresectable not responsive recurrent rectal cancer (URRC). In the present study, we have compared the safety and efficacy of HPP/target therapy, using drug regimens selected by liquid biopsy precision oncotherapy, to third-line systemic therapy based on tissue specimens precision oncotherapy. HPP/target therapy regimens were selected based on precision oncotherapy, including assays for chemosensitivity and viability, and qRT-PCR for tumor-related gene expression. In the control group, systemic third-line and further lines of therapy were defined according to clinical and biological parameters. From 2007 to 2019, 62 URRC patients were enrolled, comprised of 43 patients in the HPP/target-therapy group and 19 patients in the systemic therapy control group. No HPP related complications were reported and the most common adverse events were skin and bone marrow toxicity. In the HPP/target-therapy group, the ORR was 41.8% whereas in the systemic therapy control group was 15.8%. DCR of the HPP/target-therapy group was significantly improved over the systemic therapy group (P = 0.001), associated with a PFS of 8 vs 4 months (P = 0.009), and OS of 20 vs 8 months (P = 0.046). The present data indicate that in URCC patients, the integration of HPP/target-therapy and precision oncotherapy based upon liquid biopsy is as effective and efficacious as third-line treatment in local disease control and, therefore, deserves to be further assessed and compared to conventional systemic treatments in future prospective randomized trials.
Sections du résumé
BACKGROUND
BACKGROUND
Third line innovative systemic treatments and loco-regional chemotherapy by hypoxic pelvic perfusion (HPP) have both been proposed for the treatment of unresectable not responsive recurrent rectal cancer (URRC). In the present study, we have compared the safety and efficacy of HPP/target therapy, using drug regimens selected by liquid biopsy precision oncotherapy, to third-line systemic therapy based on tissue specimens precision oncotherapy.
METHODS
METHODS
HPP/target therapy regimens were selected based on precision oncotherapy, including assays for chemosensitivity and viability, and qRT-PCR for tumor-related gene expression. In the control group, systemic third-line and further lines of therapy were defined according to clinical and biological parameters.
RESULTS
RESULTS
From 2007 to 2019, 62 URRC patients were enrolled, comprised of 43 patients in the HPP/target-therapy group and 19 patients in the systemic therapy control group. No HPP related complications were reported and the most common adverse events were skin and bone marrow toxicity. In the HPP/target-therapy group, the ORR was 41.8% whereas in the systemic therapy control group was 15.8%. DCR of the HPP/target-therapy group was significantly improved over the systemic therapy group (P = 0.001), associated with a PFS of 8 vs 4 months (P = 0.009), and OS of 20 vs 8 months (P = 0.046).
CONCLUSIONS
CONCLUSIONS
The present data indicate that in URCC patients, the integration of HPP/target-therapy and precision oncotherapy based upon liquid biopsy is as effective and efficacious as third-line treatment in local disease control and, therefore, deserves to be further assessed and compared to conventional systemic treatments in future prospective randomized trials.
Identifiants
pubmed: 31620896
doi: 10.1007/s00432-019-03046-3
pii: 10.1007/s00432-019-03046-3
pmc: PMC6942036
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
205-219Références
Updates Surg. 2017 Sep;69(3):403-410
pubmed: 28791628
Ann Surg. 2012 Feb;255(2):281-6
pubmed: 22241290
J Biol Res (Thessalon). 2017 Sep 25;24:11
pubmed: 28975085
Arch Pathol Lab Med. 2017 May;141(5):625-657
pubmed: 28165284
Clin Cancer Res. 2004 Jan 15;10(2):411-2
pubmed: 14760058
Clin Biochem. 2016 Dec;49(18):1354-1360
pubmed: 27129799
Acta Radiol. 2014 Sep;55(7):793-801
pubmed: 24097815
World J Gastroenterol. 2017 Jun 21;23(23):4170-4180
pubmed: 28694657
Br J Surg. 2001 Jul;88(7):988-93
pubmed: 11442533
Surg Oncol Clin N Am. 2008 Oct;17(4):825-42, ix-x
pubmed: 18722921
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Br J Surg. 2018 Mar;105(4):447-452
pubmed: 29168556
Cancer Cell Int. 2014 Mar 07;14(1):23
pubmed: 24602297
N Engl J Med. 2015 May 14;372(20):1909-19
pubmed: 25970050
Oncotarget. 2018 Apr 3;9(25):17906-17914
pubmed: 29707156
J Surg Oncol. 2010 Jun 15;101(8):649-60
pubmed: 20512940
Cancer Sci. 2018 Jun;109(6):2074-2079
pubmed: 29873882
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Surg Oncol. 2007 Feb;33(1):72-8
pubmed: 17166688
Br J Surg. 2019 May;106(6):790-798
pubmed: 30776087
BMC Pharmacol Toxicol. 2013 Mar 25;14:18
pubmed: 23521834
Tumori. 2006 Sep-Oct;92(5):402-6
pubmed: 17168432
Oncotarget. 2019 Jun 11;10(39):1-13
pubmed: 31231460
Int J Oncol. 2014 Jan;44(1):17-26
pubmed: 24247407
J Clin Oncol. 2005 Mar 20;23(9):2105; author reply 2106
pubmed: 15774801
Cancer Res. 1981 Jan;41(1):73-81
pubmed: 7448778
Arch Surg. 2001 Jan;136(1):105-12
pubmed: 11146790
Lancet Oncol. 2015 Jun;16(6):619-29
pubmed: 25981818
World J Gastroenterol. 2014 Nov 28;20(44):16398-408
pubmed: 25469008
Front Med (Lausanne). 2018 Jan 30;5:9
pubmed: 29441349
J Palliat Care. 1991 Summer;7(2):6-9
pubmed: 1714502
Acta Oncol. 2008;47(6):1054-61
pubmed: 18607850
Updates Surg. 2018 Dec;70(4):441-447
pubmed: 30191532
Oncotarget. 2019 May 21;10(36):3328-3338
pubmed: 31164955
Ann Surg Oncol. 2016 Oct;23(11):3609-3615
pubmed: 27169769
Int J Clin Oncol. 2018 Feb;23(1):1-34
pubmed: 28349281
Front Biosci. 2006 May 01;11:1284-8
pubmed: 16368515
Transl Oncol. 2009 Dec;2(4):321-8
pubmed: 19956394
Ann Transl Med. 2015 Mar;3(3):36
pubmed: 25815297